Rafaèle Tordjman is now at the head of Jeito, the largest independent European fund dedicated to life sciences with 534 million euros raised.
Eighteen months after its beginnings, Jeito has made 10 equity investments in European biotechs, including three French ones (Sparing Vision, Innoskel, Alentis Therapeutics).
To discover
Taxes 2022: all about your tax return
LE FIGARO.
-Do the successes of Moderna and BioNtech portend a changing landscape for global pharmacy?
Rafaële TORDJMAN.
-
They confirm the acceleration of a trend that has existed for twenty years, namely the strength of biotechs in terms of innovation: twenty years ago, 45% of innovative drugs sold by major laboratories came from biotechs .
Today it is more than 70%.
We have seen a few major American biotechs impose themselves among Big Pharma, such as Gilead.
In Europe, they are rarer.
Read also
Health: reorganizing research, a priority
One of the reasons for their breakthrough is the development of personalized medicine.
With innovation increasingly focused on…
This article is for subscribers only.
You have 84% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for 1€ the first month
I ENJOY IT
Already subscribed?
Login
